Immunotherapy for Neurodegenerative Diseases

Immunotherapy Mechanism Pathway

flowchart TD
    %% Blue = Triggers/Inputs
    A["Abeta/Tau Protein"]:::blue --> B["Anti-Abeta/Tau<br/>Antibody"]:::blue

    %% Orange = Intermediate steps
    C["Antibody-Protein<br/>Complex"]:::orange --> D["Microglia Recognition<br/>via Fc Receptor"]:::orange

    %% Green = Outcomes
    E["Microglia<br/>Activation"]:::green --> F["Phagocytosis<br/>and Clearance"]:::green
    F --> G["Reduced Protein<br/>Aggregation"]:::green

    %% Purple = Alternative pathway
    C --> H["Peripheral<br/>Sink Effect"]:::purple
    H --> I["Bloodstream<br/>Antibody Complex"]:::purple
    I --> J["Renal/Liver<br/>Clearance"]:::purple

    %% Yellow = Decision points
    K["Passive Immunization<br/>Direct Antibody Admin"]:::yellow
    L["Active Immunization<br/>Amyloid Vaccine"]:::yellow
    K -->|"Direct Admin"| B
    L -->|"Vaccine"| M["Antigen<br/>Presentation"]:::yellow
    M --> N["T Cell<br/>Activation"]:::yellow
    N --> O["B Cell<br/>Response"]:::yellow
    O -->|"Produces"| B

    %% Click links
    click A "/proteins/app" "APP Protein"
    click A "/proteins/tau" "Tau Protein"
    click B "/therapeutics/immunotherapy" "Immunotherapy"
    click F "/mechanisms/microglia-phagocytosis" "Microglia"

    %% Color definitions
    classDef blue fill:#0a1929,stroke:#0277bd,stroke-width:2px
    classDef orange fill:#3e2200,stroke:#ef6c00,stroke-width:2px
    classDef green fill:#0e2e10,stroke:#2e7d32,stroke-width:2px
    classDef purple fill:#1a0a1f,stroke:#7b1fa2,stroke-width:2px
    classDef yellow fill:#3a3000,stroke:#f9a825,stroke-width:2px

Immunotherapy Approaches Comparison

Introduction

Overview

Immunotherapy has emerged as a transformative approach for treating neurodegenerative diseases, leveraging the immune system to target and clear pathological protein aggregates that drive disease progression. The field achieved a landmark milestone with the FDA approval of [lecanemab (Leqembi) in 2023 and donanemab (Kisunla) in 2024 for early alzheimers, demonstrating that targeting Amyloid-Beta ([Aβ)/proteins/[amyloid-beta can produce measurable clinical benefit ^{1(2025)2025 · Alzheimers DementOpen reference}. ^{1(2025)2025 · Alzheimers DementOpen reference}

Immunotherapeutic strategies for neurodegeneration encompass both passive immunization (administration of monoclonal antibodies) and active immunization (vaccination to stimulate endogenous antibody production). While anti-amyloid-beta antibodies have achieved clinical success, immunotherapies targeting tau] protein] and alpha-synuclein remain in active development, with significant challenges related to intracellular target accessibility ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}. ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}

Anti-Amyloid-Beta Immunotherapy

Passive Immunization (Monoclonal Antibodies)

Lecanemab (Leqembi)

lecanemab is a humanized IgG1 monoclonal antibody that preferentially binds amyloid-beta protofibrils — soluble aggregated forms considered the most neurotoxic species: ^{3(2024). lecanemab and donanemab as Therapies for Alzheimer's Disease. *eNeuro*. DOI2024Open reference}

• Mechanism: Targets amyloid-beta protofibrils and large soluble oligomers, promoting their clearance through microglial phagocytosis

• CLARITY AD trial: 27% slowing of cognitive decline on CDR-SB over 18 months in early AD (MCI and mild dementia)

• Amyloid reduction: Achieved significant reduction in amyloid-pet signal, with 68% of participants becoming amyloid-negative

• Dosing: 10 mg/kg IV biweekly

• FDA approval: Full approval January 2023; expanded labeling to include subcutaneous formulation in 2025 ^{3(2024). lecanemab and donanemab as Therapies for Alzheimer's Disease. *eNeuro*. DOI2024Open reference}

Donanemab (Kisunla)

donanemab targets pyroglutamate-modified amyloid-beta (AβpE3), a form present predominantly in established amyloid plaques: ^{4(2025)2025 · Egypt J Neurol Psychiatry NeurosurgOpen reference}

• Mechanism: Binds N-terminal pyroglutamate amyloid-beta (AβpE3-42) in deposited plaques, promoting rapid amyloid clearance via Fc receptor-mediated microglial phagocytosis

• TRAILBLAZER-ALZ 2 trial: 35% slowing of cognitive decline on iADRS in the combined tau]-low/medium population over 18 months

• Amyloid reduction: 84% of patients achieved amyloid clearance at 18 months, enabling treatment discontinuation

• Dosing: 700 mg IV monthly for 3 doses, then 1,400 mg monthly; discontinuation protocol when amyloid clearance achieved

• FDA approval: July 2024 for early symptomatic AD ^{4(2025)2025 · Egypt J Neurol Psychiatry NeurosurgOpen reference}

Aducanumab (Aduhelm) — Discontinued

Aducanumab was the first anti-amyloid antibody to receive FDA accelerated approval (June 2021), targeting aggregated forms of amyloid-beta including fibrils and plaques: ^{5(2025). Recent Advances in Antibody Therapy for Alzheimer''s Disease: Focus on Bispecific Antibodies. *Int J Mol Sci*. DOI2025Open reference}

• Mixed clinical results across Phase III trials (EMERGE positive, ENGAGE negative)

• Significant controversy over accelerated approval based on amyloid reduction as surrogate endpoint

• Discontinued from the market in November 2024 due to limited commercial uptake

• Provided critical lessons about trial design, patient selection, and the amyloid hypothesis ^{1(2025)2025 · Alzheimers DementOpen reference}

Next-Generation Anti-Aβ Antibodies

Several next-generation antibodies are in development: ^{1(2025)2025 · Alzheimers DementOpen reference}0

• Remternetug: Eli Lilly’s subcutaneous anti-pyroglutamate amyloid-beta antibody, designed for monthly dosing with potentially faster amyloid clearance

• Trontinemab: Roche’s brain-shuttle anti-Aβ antibody using transferrin receptor-mediated transcytosis to enhance blood-brain-barrier penetration

• Bispecific antibodies: Novel constructs targeting multiple epitopes or combining Aβ targeting with enhanced blood-brain-barrier crossing ^{1(2025)2025 · Alzheimers DementOpen reference}1

Active Immunization (Vaccines)

Early Lessons: AN-1792

The first Aβ vaccine trial (AN-1792) was halted in 2002 when 6% of participants developed meningoencephalitis, caused by a pro-inflammatory T-cell response to the full-length Aβ1-42 peptide. Post-mortem analysis revealed near-complete amyloid clearance in some participants, providing proof-of-concept despite the safety failure. ^{1(2025)2025 · Alzheimers DementOpen reference}2

Current Vaccine Development

Second-generation vaccines use shortened Aβ fragments to elicit antibody responses without T-cell activation: ^{1(2025)2025 · Alzheimers DementOpen reference}3

• ABvac40: Targets the C-terminal end of Aβ40; Phase II results showed robust anti-Aβ40 antibody response with favorable safety

• UB-311: CpG-adjuvanted Aβ1-14 peptide vaccine; Phase II demonstrated anti-Aβ antibody generation and acceptable safety

• ACI-24.060: Liposomal vaccine displaying Aβ1-15 peptide; in Phase II for Down syndrome-associated AD and early-onset AD

Anti-Tau Immunotherapy

Targeting tau pathology] represents the next frontier in neurodegeneration immunotherapy. Unlike amyloid, tau-protein correlates more closely with cognitive decline and neuronal loss. However, tau is predominantly intracellular, presenting unique therapeutic challenges ^{1(2025)2025 · Alzheimers DementOpen reference}4. ^{1(2025)2025 · Alzheimers DementOpen reference}5

Passive Anti-Tau Antibodies

To date, 14 anti-tau antibodies have been evaluated in clinical trials for tauopathies: ^{1(2025)2025 · Alzheimers DementOpen reference}6

• Semorinemab (RO7105705): Anti-tau antibody targeting the N-terminal domain. Phase II LAURIET trial in moderate AD showed significant slowing of functional decline (ADCS-ADL) but no benefit on cognition (ADAS-Cog) — an unexpected dissociation.

• Bepranemab (UCB0107): Targets the mid-domain of tau, inhibiting cell-to-cell tau propagation]. Phase II in early AD ongoing.

• Zagotenemab (LY3303560): Targets conformational changes in aggregated tau. Phase II trial discontinued after failing to demonstrate clinical benefit.

• Tilavonemab (ABBV-8E12): Anti-tau antibody tested in psp; Phase II failed primary endpoint.

• E2814: Targets the microtubule-binding region of tau; being tested in the DIAN-TU prevention trial for dominantly inherited AD ^{1(2025)2025 · Alzheimers DementOpen reference}7.

Active Anti-Tau Vaccines

• ACI-35.030: Liposomal vaccine displaying phosphorylated tau peptide (pS396/pS404); Phase Ib/IIa showed robust anti-phospho-tau antibody responses

• AADvac1: Active vaccine targeting mis-disordered tau (amino acids 294–305); Phase II ADAMANT trial showed signals in specific biomarker subgroups

Challenges with Anti-Tau Immunotherapy

The clinical failure of most anti-tau antibodies reflects fundamental challenges: ^{1(2025)2025 · Alzheimers DementOpen reference}8

• Tau pathology is predominantly intracellular, limiting antibody access

• Extracellular tau represents a small fraction of total pathological tau

• Optimal tau epitope for therapeutic targeting remains unclear (N-terminal, mid-domain, or phospho-epitopes)

• Tau propagation] may occur through multiple mechanisms beyond extracellular transfer

• Patient heterogeneity in tau isoform composition and phosphorylation patterns ^{1(2025)2025 · Alzheimers DementOpen reference}9

Anti-alpha-synuclein Immunotherapy

Targeting alpha-synuclein is the primary immunotherapeutic strategy for parkinsons, lewy-body-dementia, and msa. ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}0

Passive Anti-α-Synuclein Antibodies

Five anti-α-synuclein antibodies have entered clinical trials:

• Prasinezumab (PRX002/RO7046015): Targets aggregated α-synuclein. Phase II PASADENA trial showed trends toward motor benefit on MDS-UPDRS Part III but missed primary endpoint. Phase IIb PADOVA trial ongoing with enriched population ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}1.

• Cinpanemab (BIIB054): Targets aggregated α-synuclein N-terminus. Phase II SPARK trial discontinued after interim analysis showed no efficacy.

• MEDI1341 (Lu AF87908): Targets monomeric and aggregated α-synuclein; Phase I demonstrated dose-dependent CSF free α-synuclein reduction.

• Lu AF82422: Anti-α-synuclein antibody in Phase I/II for MSA.

Active Anti-α-Synuclein Vaccines

• UB-312: Active peptide vaccine targeting the C-terminal region of α-synuclein; Phase I showed immunogenicity and acceptable safety

• AFFITOPE PD01A/PD03A: Short peptide mimotopes designed to elicit anti-α-synuclein antibodies; Phase I completed

• ACI-7104.056: Anti-α-synuclein vaccine in preclinical development

Challenges with Anti-α-Synuclein Immunotherapy

Like tau, α is primarily intracellular (Lewy bodies and Lewy neurites), limiting antibody access. Other challenges include:

• Disease heterogeneity within the synucleinopathy spectrum

• Difficulty demonstrating target engagement in vivo (no approved α-synuclein PET tracer)

• Potential protective roles of extracellular α-synuclein that antibody clearance might disrupt

• Optimal timing for intervention remains unknown ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}2

Amyloid-Related Imaging Abnormalities (ARIA)

ARIA is the most significant safety concern with anti-amyloid immunotherapy:

ARIA-E (Edema/Effusion)

• Vasogenic edema and sulcal effusion on MRI

• Occurs in 12–35% of patients depending on the antibody

• Higher incidence in apoe4 burden increases risk

• Rarely symptomatic but may be irreversible

Risk Mitigation

• Mandatory [APOE genotyping before treatment initiation

• Baseline and periodic MRI monitoring (approximately every 3 months during dose escalation)

• Enhanced monitoring for APOE4 homozygotes

• Shared decision-making regarding risk-benefit profile ^{2(2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. *Transl Neurodegener*. DOI2025Open reference}3

Immunomodulatory Approaches

Beyond targeting pathological proteins, immunomodulatory strategies aim to reshape the neuroinflammatory environment:

Microglial Modulation

• trem2 agonists: Antibodies activating trem2 to enhance microglial phagocytosis and reduce neuroinflammation. AL002 (Alector) is in Phase II for AD.

• Anti-CD33 antibodies: CD33 is a negative regulator of microglial phagocytosis; blocking antibodies aim to enhance Aβ clearance.

• Colony-stimulating factor 1 receptor (CSF1R) modulators: Modulate microglial to prevent synapse elimination in AD.

Future Directions

1. Combination immunotherapy: Simultaneous targeting of Aβ and tau, or protein targets combined with anti-inflammatory approaches

2. Brain-penetrant antibody engineering: Transferrin receptor-mediated transcytosis and other strategies to increase CNS antibody levels

3. Intrabodies and nanobodies: Single-domain antibodies that can access intracellular compartments to target tau and α-synuclein aggregates

4. Prevention trials: Deploying anti-amyloid immunotherapy in presymptomatic individuals (AHEAD 3-45, A45-INJECT, DIAN-TU studies)

5. Biomarker-guided treatment: Using plasma p-tau217, amyloid PET, and tau PET to select patients and monitor treatment response

6. Subcutaneous formulations: Improving patient convenience and potentially reducing infusion-related reactions

See Also

• Clinical Trials Index

• [gene-therapy

Background

The study of Immunotherapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

External Links

• AbbVie - Duodopa

• Parkinson’s Foundation - Duodopa

• PubMed - Levodopa Carbidopa Intestinal Gel

• Movement Disorder Society - Infusion Therapy

• Mayo Clinic - Parkinson’s Advanced Treatment